A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed. Academic Article uri icon

Overview

abstract

  • INTRODUCTION: In the phase I and II trials, the dose-limiting toxicities of pemetrexed included neutropenia, thrombocytopenia, and fatigue. Grade 3 bilateral peripheral edema that resembled cellulitis was not commonly described. METHODS: Since 2009, the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center has identified 14 patients who developed bilateral peripheral edema and erythema of the lower extremities while receiving pemetrexed chemotherapy. During this time, 489 patients with thoracic malignancy have been treated with pemetrexed. RESULTS: There were seven men and seven women. Average age was 72 years. All patients had stage IV adenocarcinoma of the lung. The edema presented at a median of eight doses (range, 3-23 doses.) Other causative factors such as deep vein thrombosis, renal insufficiency, and congestive heart failure were excluded. Thirteen of the 14 patients required the drug to be stopped or dose lowered. CONCLUSION: We have collected 14 cases with lung adenocarcinoma treated with pemetrexed who developed bilateral lower extremity edema and erythema, a condition rarely described. In all cases, symptoms resolved with discontinuation or dose reduction of the drug. Patients who received corticosteroids showed improvement in their symptoms.

publication date

  • March 1, 2011

Research

keywords

  • Adenocarcinoma
  • Antimetabolites, Antineoplastic
  • Edema
  • Glutamates
  • Guanine
  • Lung Neoplasms
  • Thoracic Neoplasms

Identity

Scopus Document Identifier

  • 79951742820

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e318207f788

PubMed ID

  • 21317741

Additional Document Info

volume

  • 6

issue

  • 3